CLINICAL TRIAL SUMMARY

MDACC Study No:2004-0816 (clinicaltrials.gov NCT No: NCT00508872)
Title:SINGLE-INSTITUTION PHASE II TRIAL OF OXALIPLATIN,
5-FLUOROURACIL, LEUCOVORIN AND BEVACIZUMAB (FOLFOX-B) FOR INITIALLY UNRESECTABLE COLORECTAL LIVER METASTASES: DOWNSTAGING FOLLOWED BY HEPATIC RESECTION
Principal Investigator:Eddie Abdalla
Treatment Agent:5-Fluorouracil; Bevacizumab; Leucovorin; Oxaliplatin
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if combination treatment
with oxaliplatin (L-OHP), 5-fluorouracil (5-FU), leucovorin (LV), and
bevacizumab (Avastin) before surgery can decrease the size of the tumors in the
liver so that any cancer in the liver can be removed by surgery.

Hide details for General InformationGeneral Information

Disease Group:Colorectal; Liver
Phase of Study:Phase II
Treatment Agents:5-Fluorouracil
Bevacizumab
Leucovorin
Oxaliplatin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients will have CT scan of abdomen/pelvis/chest and CXR and CBC, blood
chemistries and CEA every 3 months for 3 years after completion of treatment.
PET scan every 6 months for 3 years after completion of treatment.
Home Care:Anti-emetics prescribed in protocol as needed. Infusion 5-FU runs continuously
46 hours.
Patients may choose to receive chemotherapy treatment from their home medical
oncologist.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Eddie Abdalla
Dept:Surgical Oncology
For Clinical Trial Enrollment:713-792-6940
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults